Divi’s Laboratories – Q1 FY27 EARNINGS CALL HIGHLIGHTS
#Q1FY27
Management Commentary
– Strong execution continued.
– Custom synthesis accelerated.
– Generic business remained resilient.
– Peptides remained strategic priority.
– Capex projects nearing completion.
– Backward integration strengthened.
– Manufacturing reliability improved.
– Double-digit growth outlook maintained.
Financial Performance
– Total Income: ₹3,144 Cr (+24% YoY).
– PAT: ₹902 Cr (+66% YoY).
– PBT: ₹1,180 Cr (+61% YoY).
– Exports: 90% of revenue.
– Custom Synthesis: 60% mix.
– Generics: 40% mix.
– Nutraceutical Revenue: ₹298 Cr (+19%).
– Cash & Equivalents: ₹3,611 Cr.
Business Performance
– Generic volumes remained stable.
– Pricing stayed competitive.
– Peptide pipeline expanded.
– Multiple customer validations ongoing.
– Three major projects validating.
– 20 commercial CDMO projects.
– Europe & North America dominant.
– Backward integration enhanced.
Growth Initiatives
– Peptide capacity expanding.
– Additional SPPS reactors planned.
– Continuous flow chemistry adopted.
– Biocatalysis capabilities strengthened.
– Automation investments continued.
– Green chemistry initiatives expanded.
– Process intensification progressing.
– Unit-3 role increasing.
Operational Highlights
– Three-month inventory strategy.
– Unit utilization: 80–85%.
– ₹451 Cr assets capitalized.
– CWIP: ₹2,034 Cr.
– Three capex projects ~70% complete.
– Raw material sourcing diversified.
– Logistics managed efficiently.
– Technology capabilities strengthened.
Management Guidance
– Double-digit revenue growth.
– Custom synthesis momentum sustained.
– Commercial supplies after approvals.
– Peptide investments to continue.
– Margins to remain quarterly volatile.
– Annual margin focus maintained.
– Validation pipeline progressing.
– Long-term growth outlook positive.
Key Positives
– Strong earnings growth.
– Robust custom synthesis.
– Healthy cash position.
– Expanding peptide platform.
– Integrated manufacturing advantage.
– Capex nearing completion.
– Stable generic business.
– Strong customer pipeline.
– Supply chain resilience.
– Backward integration benefits.
Key Challenges
– Solvent cost inflation.
– Geopolitical uncertainty.
– Logistics disruptions.
– Elevated freight costs.
– Raw material volatility.
– Regulatory approval timelines.
– Quarterly revenue lumpiness.
– Customer confidentiality restrictions.
Management Tone
– Highly confident.
– Execution-focused.
– Long-term optimistic.
– Growth-oriented.
Key Takeaway
– Divi’s Laboratories is entering its next growth phase, supported by strong custom synthesis momentum, expanding peptide capabilities, integrated manufacturing, and multiple late-stage customer programs, while maintaining a disciplined long-term execution strategy despite near-term supply chain volatility.
Clean Science & Technology – Q1 FY27 EARNINGS CALL HIGHLIGHTS
#Q1FY27
Management Commentary
– Record quarterly sales achieved.
– HALS business scaling strongly.
– Supply chain challenges persisted.
– Demand environment remained stable.
– Product mix improved.
– Strategic partnerships announced.
– Commercialization milestones progressing.
– Long-term outlook remained positive.
Financial Performance
– Consolidated Revenue: ₹264 Cr (+10% YoY).
– Standalone Revenue: ₹203 Cr (+5% QoQ).
– Standalone EBITDA: ₹87 Cr.
– Standalone EBITDA Margin: 43%.
– Standalone PAT: ₹73 Cr.
– Consolidated EBITDA: ₹96 Cr.
– Consolidated EBITDA Margin: 37%.
– Consolidated PAT: ₹73 Cr.
Business Performance
– HALS: 22% of sales.
– HALS exports: ~50% of sales.
– HALS volume: ~1,000 MT.
– HALS realization improved.
– Legacy demand remained steady.
– Performance Chemicals: 83% mix.
– Pharma: 10% mix.
– FMCG: 7% mix.
Growth Initiatives
– Swiss Genius Kem partnership.
– Advanced NOR HALS launch.
– Joint global marketing planned.
– Hydroquinone plant ramping up.
– Performance Chemical-2 in Q3.
– Kemin five-year agreement signed.
– Export penetration increasing.
– Higher-grade HALS expansion.
Operational Highlights
– Highest-ever quarterly sales.
– CFCL became self-sustaining.
– HALS export mix diversified.
– ₹100 Cr infused into CFCL.
– Total CFCL investment: ₹850 Cr.
– Higher-grade HALS increasing.
– Customer approvals received.
– Commercial ramp-up underway.
Management Guidance
– HALS Revenue: ₹250–300 Cr FY27.
– Performance Chemical-2: Q3 FY27.
– Hydroquinone revenues to rise.
– EBITDA margins to improve.
– Higher-grade HALS mix increasing.
– New HALS plant: Q3 FY27.
– Supply chain normalization expected.
– Long-term growth remains strong.
Key Positives
– Record quarterly revenue.
– Strong HALS growth.
– Improving product mix.
– Premium export expansion.
– Swiss technology partnership.
– Five-year Kemin agreement.
– Higher operating leverage.
– Margin improvement potential.
– Strong customer approvals.
– Diversified revenue profile.
Key Challenges
– Raw material inflation.
– Middle East disruptions.
– Freight cost pressures.
– Vessel availability issues.
– Export logistics delays.
– Limited pricing pass-through.
– China cost advantage.
– Commodity volatility.
Management Tone
– Highly confident.
– Growth-focused.
– Execution-driven.
– Optimistic.
Key Takeaway
– Clean Science is entering its next growth phase, driven by rapid HALS scale-up, premium product expansion, strategic global partnerships, and improving operating leverage, while navigating temporary supply chain and raw material headwinds.
|
Read More article like this on vivekananda-college.org
